Overcoming resistance to immunotherapy by teaching old drugs new tricks

Cancer stem cells (CSCs) underlie resistance to therapy. Cancer develops only in the context of failing immunosurveillance, and stem cells occupy immune privileged microenvironments. Recent evidence demonstrates that CSCs borrow immune privilege from their normal counterparts. However, low doses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Perry, John M., Li, Linheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469442/
https://www.ncbi.nlm.nih.gov/pubmed/32944648
http://dx.doi.org/10.1080/23723556.2020.1801088
_version_ 1783578426957889536
author Perry, John M.
Li, Linheng
author_facet Perry, John M.
Li, Linheng
author_sort Perry, John M.
collection PubMed
description Cancer stem cells (CSCs) underlie resistance to therapy. Cancer develops only in the context of failing immunosurveillance, and stem cells occupy immune privileged microenvironments. Recent evidence demonstrates that CSCs borrow immune privilege from their normal counterparts. However, low doses of doxorubicin can target CSCs by restoring anticancer immunity.
format Online
Article
Text
id pubmed-7469442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74694422020-09-28 Overcoming resistance to immunotherapy by teaching old drugs new tricks Perry, John M. Li, Linheng Mol Cell Oncol Author's Views Cancer stem cells (CSCs) underlie resistance to therapy. Cancer develops only in the context of failing immunosurveillance, and stem cells occupy immune privileged microenvironments. Recent evidence demonstrates that CSCs borrow immune privilege from their normal counterparts. However, low doses of doxorubicin can target CSCs by restoring anticancer immunity. Taylor & Francis 2020-08-12 /pmc/articles/PMC7469442/ /pubmed/32944648 http://dx.doi.org/10.1080/23723556.2020.1801088 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's Views
Perry, John M.
Li, Linheng
Overcoming resistance to immunotherapy by teaching old drugs new tricks
title Overcoming resistance to immunotherapy by teaching old drugs new tricks
title_full Overcoming resistance to immunotherapy by teaching old drugs new tricks
title_fullStr Overcoming resistance to immunotherapy by teaching old drugs new tricks
title_full_unstemmed Overcoming resistance to immunotherapy by teaching old drugs new tricks
title_short Overcoming resistance to immunotherapy by teaching old drugs new tricks
title_sort overcoming resistance to immunotherapy by teaching old drugs new tricks
topic Author's Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469442/
https://www.ncbi.nlm.nih.gov/pubmed/32944648
http://dx.doi.org/10.1080/23723556.2020.1801088
work_keys_str_mv AT perryjohnm overcomingresistancetoimmunotherapybyteachingolddrugsnewtricks
AT lilinheng overcomingresistancetoimmunotherapybyteachingolddrugsnewtricks

Ejemplares similares